Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes

Sanofi and the Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School, have announced a new collaboration to promote the development of new medicines for the treatment of diabetes and related disorders. The collaboration was unveiled at the 2012 Bio International Convention in Boston, Mass...

Read full story >>

AstraZeneca completes acquisition of Ardea Biosciences
AstraZeneca announced that on Tuesday 19 June 2012 it completed its acquisition of San Diego, California-based biotechnology company Ardea Biosciences, Inc...

Roche and Seaside Therapeutics announce landmark alliance to advance novel treatments for FXS and ASD
Roche and Seaside Therapeutics announced that they have entered into a collaboration to develop disease modifying treatments for fragile X syndrome (FXS) and autism spectrum disorders (ASD)...

Positive results from Phase 3 study PROFILE 1007 evaluating XALKORI® (crizotinib) in previously treated patients with ALK-Positive advanced NSCLC
Pfizer Inc. announced that the PROFILE 1007 study met its primary endpoint...

Geisinger & Merck to collaborate on multi-year effort to improve patient adherence, engagement & care delivery
Geisinger Health System and Merck have announced a new multi-year collaboration designed to improve patient health outcomes...

EMA validates Gilead’s marketing application for Elvitegravir for treatment of HIV infection
Gilead Sciences, Inc. announced that its Marketing Authorisation Application for elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced patients, has been validated by the EMA...

FDA issues complete response letter for Pfizer’s tafamidis meglumine New Drug Application
Pfizer Inc. announced that it has received a Complete Response Letter from the U.S. FDA on its New Drug Application for tafamidis meglumine...

Boehringer Ingelheim BioXcellence: Distinctive brand for the biopharmaceutical contract manufacturing business
With Boehringer Ingelheim BioXcellence the pharmaceutical company Boehringer Ingelheim set up an own brand for its biopharmaceutical contract manufacturing business...

Abbott presents results of clinical studies evaluating its investigational treatment for advanced Parkinson’s disease
Abbott announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for advanced Parkinson’s disease...

AF patients who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa®) compared to warfarin
Findings published in Circulation demonstrate that Pradaxa® (dabigatran etexilate) is associated with a substantially shorter interruption of oral anticoagulation therapy compared to warfarin...

TSI inc. interviewed at Interphex 2012
Troy Tillman, Senior Global Marketing Manager, TSI inc. speaks to Freddy White at Interphex 2012.

AMRI interviewed at Interphex 2012
Tony Ramy, Senior Director Business Development, AMRI speaks to Freddy White at Interphex 2012.

Freeman Technology interviewed at Interphex 2012
Tim Freeman, Managing Director, Freeman Technology speaks to Freddy White at Interphex 2012.

GEA interviewed at Interphex 2012
McCoy Knight, National Sales Manager, GEA speaks to Freddy White at Interphex 2012.

Umetrics interviewed at Interphex 2012
Amos Dor, Director of Sales and Operations, Umetrics speaks to Freddy White at Interphex 2012.